Positive Results from POZEN Phase 1 Study Presented At AHA

POZEN Inc. (NASDAQ: POZN), presented positive results today from a Phase 1 study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated omeprazole, enteric-coated aspirin and clopidogrel . In the Co-Rx study, PA32540, a novel combination of 325 mg of aspirin and 40 mg immediate-release omeprazole, when dosed 10 hours apart from clopidogrel, was associated with greater platelet inhibition than synchronous administration of aspirin, clopidogrel and delayed-release omeprazole (46.5% versus 39.3%), respectively, at day 7. These findings are directly relevant to the treatment of patients with gastrointestinal (GI) risk who require dual antiplatelet therapy and gastroprotection. The data was presented at the American Heart Association's 2011 Scientific Sessions in Orlando, Florida.